{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:48:16Z","timestamp":1782809296553,"version":"3.54.5"},"reference-count":41,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer is a major cause of gynecological cancer mortality, frequently associated with platinum-resistant recurrences. Given the limited efficacy of conventional chemotherapy in this setting, alternative targeted therapeutics are needed. Mirvetuximab soravtansine (MIRV) is an antibody\u2013drug conjugate designed to deliver the cytotoxic maytansinoid DM4 to folate receptor alpha (FR\u03b1)-overexpressing cells. This systematic review of PubMed, ClinicalKey, and SpringerLink databases (2019\u20132026) evaluates five publications across three clinical trials (one phase II, two phase III) encompassing 925 patients with platinum-resistant disease. Notably, the phase III MIRASOL trial demonstrated improved survival outcomes with MIRV over standard chemotherapy, extending median overall survival (16.46 vs. 12.75 months; HR 0.67) and progression-free survival (5.62 vs. 3.98 months; HR 0.65), with an objective response rate (ORR) of 42.3% versus 15.9%. Furthermore, the single-arm phase II SORAYA trial reported an ORR of 32.4% in pretreated patients, including those with prior PARP inhibitor and bevacizumab exposure. Although the preceding FORWARD I trial missed its primary endpoint in the unselected population, its high-FR\u03b1 subgroup analysis revealed a clinical benefit that influenced subsequent biomarker-driven enrollment strategies. From a safety perspective, MIRV exhibited lower rates of severe neutropenia and anemia than chemotherapy, with toxicities primarily consisting of manageable, reversible ocular events. Ultimately, MIRV serves as a therapeutic option for platinum-resistant, FR\u03b1-positive ovarian cancer, offering survival advantages; however, rigorous biomarker-based screening remains necessary to optimize therapeutic outcomes.<\/jats:p>","DOI":"10.3390\/ijms27135887","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:26:15Z","timestamp":1782807975000},"page":"5887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mirvetuximab Soravtansine in the Treatment of Chemotherapy-Resistant Ovarian Cancer: A Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2460-1747","authenticated-orcid":false,"given":"Natalia","family":"Picheta","sequence":"first","affiliation":[{"name":"Student\u2019s Scientific Association\u2014I Chair and Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Staszica 16 Str., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2211-1413","authenticated-orcid":false,"given":"Julia","family":"Piekarz","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association\u2014I Chair and Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Staszica 16 Str., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Pobide\u0142","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association\u2014I Chair and Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Staszica 16 Str., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-433X","authenticated-orcid":false,"given":"Karolina","family":"Dani\u0142owska","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association\u2014I Chair and Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Staszica 16 Str., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gierulska","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association\u2014I Chair and Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Staszica 16 Str., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-484X","authenticated-orcid":false,"given":"Krzysztof","family":"Ku\u0142ak","sequence":"additional","affiliation":[{"name":"I Chair and Department of Gynecological Oncology and Gynecology, Medical University of Lublin, Staszica 16 Str., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6820-2556","authenticated-orcid":false,"given":"Anna","family":"Ku\u0142ak","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Microsurgery of Glaucoma, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7574-2653","authenticated-orcid":false,"given":"Ewa","family":"Tomaszewska","sequence":"additional","affiliation":[{"name":"Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences, Akademicka 13, 20-950 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-1960","authenticated-orcid":false,"given":"Iwona","family":"Puzio","sequence":"additional","affiliation":[{"name":"Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences, Akademicka 13, 20-950 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Biernacka, K., \u0141ukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., and Makowska, M. (2025). Ovarian Cancer\u2014Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors\u2019 Molecular Backgrounds. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104611"},{"key":"ref_2","first-page":"100629","article-title":"Epithelial ovarian cancer: Review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","journal-title":"Med. J. Aust."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jama.2024.9210","article-title":"Endometriosis Typology and Ovarian Cancer Risk","volume":"332","author":"Barnard","year":"2024","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Samuel, D., Diaz-Barbe, A., Pinto, A., Schlumbrecht, M., and George, S. (2022). Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2. Cells, 11.","DOI":"10.3390\/cells11030539"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.21873\/anticanres.15111","article-title":"Multimodal Treatment of Primary Advanced Ovarian Cancer","volume":"41","author":"Friedrich","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_9","unstructured":"(2026, March 16). Mirvetuximab (M9346A)|Anti-FOLR1 mAb|MedChemExpress. MedchemExpress.com. Available online: https:\/\/www.medchemexpress.com\/mirvetuximab.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11795549231187264","DOI":"10.1177\/11795549231187264","article-title":"Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer","volume":"17","author":"Veneziani","year":"2023","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: Current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ajhp\/zxaf011","article-title":"A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer","volume":"82","author":"Smith","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e70447","DOI":"10.1111\/cts.70447","article-title":"Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science","volume":"19","author":"Menon","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: First antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_18","unstructured":"US Food and Drug Administration (2026, March 16). FDA Approves Mirvetuximab Soravtansine-Gynx for FR\u03b1 Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian."},{"key":"ref_19","unstructured":"(2026, March 16). Elahere|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elahere."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)-high platinum-resistant ovarian cancer: Final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: Primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: A randomised, open-label, phase 3 trial","volume":"26","author":"Moore","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_25","unstructured":"(2026, March 16). Ovarian-Polish.pdf. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian-polish.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1002\/cncr.32500","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"125","author":"Pignata","year":"2019","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104434","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: The single-arm phase II PICCOLO trial","volume":"36","author":"Lewin","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102879","DOI":"10.1016\/j.ijgc.2025.102879","article-title":"Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: A retrospective real-world analysis","volume":"36","author":"Roberts","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_34","unstructured":"(2026, March 16). Mirvetuximab Soravtansine, a Folate Receptor Alpha (FR\u03b1)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients (Pts) with Platinum-Agnostic Ovarian Cancer: Final Analysis\u2014ASCO. Available online: https:\/\/www.asco.org\/abstracts-presentations\/195544."},{"key":"ref_35","unstructured":"AbbVie (2026, March 16). Randomized, Multicenter, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine in Combination with Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients with FR\u03b1-High Recurrent Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab. Clinicaltrials.gov, Clinical Trial Registration NCT05445778, February 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05445778."},{"key":"ref_36","unstructured":"(2026, May 23). AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-Gynx (ELAHERE\u00ae) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026. AbbVie News Center. Available online: https:\/\/news.abbvie.com\/2026-04-12-AbbVie-Showcases-Late-Breaking-Phase-2-Data-for-Mirvetuximab-Soravtansine-gynx-ELAHERE-R-in-Platinum-Sensitive-Ovarian-Cancer-PSOC-at-SGO-2026."},{"key":"ref_37","unstructured":"(2026, March 18). Integrated Safety Summary of Single-Agent Mirvetuximab Soravtansine in Patients with Folate Receptor \u03b1 (FR\u03b1)-Positive Recurrent Ovarian Cancer: Phase 1 and 3 Clinical Trials\u2014ASCO. Available online: https:\/\/www.asco.org\/abstracts-presentations\/207693."},{"key":"ref_38","unstructured":"(2026, March 19). Antibody-Drug Conjugates and Ocular Toxicities: A Call for Standardized Guidelines\u20142025. American Academy of Ophthalmology. Available online: https:\/\/www.aao.org\/education\/clinical-statement\/antibody-drug-conjugates-ocular-toxicities-call-st."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha\u2013expressing recurrent ovarian cancer: An integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102867","DOI":"10.1016\/j.ctrv.2024.102867","article-title":"Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies","volume":"134","author":"Rousseau","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"115522","DOI":"10.1016\/j.ejca.2025.115522","article-title":"Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer","volume":"224","author":"Porter","year":"2025","journal-title":"Eur. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:38:36Z","timestamp":1782808716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":41,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135887"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135887","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}